Updated:
Beiley Biofund
Beiley Biofund is a Taipei-based private equity asset manager focused on early-stage investments.
Beiley Biofund
Beiley Biofund invests in early-stage healthcare and capital market companies. The firm provides technical expertise and capital market services to its portfolio companies. Based in Taipei, Taiwan, Beiley Biofund has made 7 investments, including a Series C investment in Libo Pharma on July 21, 2025.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
Taiwan
City
Taipei City
Corporate office
Taipei City, Taiwan
Sector focus
Frequently asked questions
Who runs investment decisions at Beiley Biofund?
No named principals or investment committee members are disclosed in available sources.
What investment stages does Beiley Biofund target?
The firm focuses on early-stage opportunities according to its strategy descriptors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: